Results 161 to 170 of about 3,679,356 (272)

Novel approaches to the use of hypomethylating agents in myeloid malignancies. [PDF]

Epigenomics
Cheng J, O'Connell C, O'Connell C.
europepmc   +1 more source

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors. [PDF]

Ann Hematol
Jovein MM, Meyer T, Waterhouse M, Pfeifer D, Duque-Afonso J, Lübbert M, Maas-Bauer K, Wäsch R, Bertz H, Duyster J, Zeiser R, Finke J, Wehr C.   +12 more
europepmc   +1 more source

Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches. [PDF]

Clin Hematol Int
Cortiana V, Vallabhaneni H, Ghazal J, Itodo K, Kassim Dohadwala T, Park C, Leyfman Y.   +6 more
europepmc   +1 more source

BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer [PDF]

, 2016
Gomes, AR, Gong, C, Lam, EW, Yao, S
core   +1 more source

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? [PDF]

Ann Hematol
Tarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F.   +30 more
europepmc   +1 more source

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. [PDF]

Hemasphere
Vänttinen I, Saad J, Ruokoranta T, Kytölä S, Qin G, Tercan B, Ettala P, Partanen A, Pyörälä M, Rimpiläinen J, Siitonen T, Manninen M, Valk PJM, Huls G, Thorsson V, Heckman CA, Kontro M, Kuusanmäki H.   +17 more
europepmc   +1 more source

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents. [PDF]

Ther Adv Hematol
Zeidan AM, Zhao R, Tepsick JG, Lan Z, Salimi T.   +4 more
europepmc   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]

Eur J Haematol
Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C, Mendicino F, Lucia E, Olivito V, Amodio N, Morabito F, Gentile M.   +11 more
europepmc   +1 more source

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review. [PDF]

Front Oncol
Mi R, Guo S, Yang W, Wang L, Ma Y, Chen L, Li D, Wei X.   +7 more
europepmc   +1 more source

Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source